Acurx Pharmaceuticals Statistics
Share Statistics
Acurx Pharmaceuticals has 16.89M shares outstanding. The number of shares has increased by 24.91% in one year.
| Shares Outstanding | 16.89M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 2.67% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 14.49M |
| Failed to Deliver (FTD) Shares | 18 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 474.48K, so 2.81% of the outstanding shares have been sold short.
| Short Interest | 474.48K |
| Short % of Shares Out | 2.81% |
| Short % of Float | 3.3% |
| Short Ratio (days to cover) | 12.59 |
Valuation Ratios
The PE ratio is -3.33 and the forward PE ratio is -1.19.
| PE Ratio | -3.33 |
| Forward PE | -1.19 |
| PS Ratio | 0 |
| Forward PS | 1.4 |
| PB Ratio | 10.4 |
| P/FCF Ratio | -4.95 |
| PEG Ratio | n/a |
Enterprise Valuation
Acurx Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 2.53, with a Debt / Equity ratio of 0.
| Current Ratio | 2.53 |
| Quick Ratio | 2.53 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -3.12% and return on capital (ROIC) is -312.38%.
| Return on Equity (ROE) | -3.12% |
| Return on Assets (ROA) | -1.89% |
| Return on Capital (ROIC) | -312.38% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -3.64M |
| Employee Count | 4 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -75.71% in the last 52 weeks. The beta is -1.72, so Acurx Pharmaceuticals 's price volatility has been lower than the market average.
| Beta | -1.72 |
| 52-Week Price Change | -75.71% |
| 50-Day Moving Average | 1.62 |
| 200-Day Moving Average | 2.06 |
| Relative Strength Index (RSI) | 27.24 |
| Average Volume (20 Days) | 120.21K |
Income Statement
In the last 12 months, Acurx Pharmaceuticals had revenue of $0 and earned -$14.58M in profits. Earnings per share was $-1.15.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -14.58M |
| Net Income | -14.58M |
| EBITDA | 0 |
| EBIT | - |
| Earnings Per Share (EPS) | -1.15 |
Balance Sheet
The company has $7.47M in cash and $0 in debt, giving a net cash position of $7.47M.
| Cash & Cash Equivalents | 7.47M |
| Total Debt | 0 |
| Net Cash | 7.47M |
| Retained Earnings | -53.22M |
| Total Assets | 5.98M |
| Working Capital | -3.31B |
Cash Flow
In the last 12 months, operating cash flow was -$9.80M and capital expenditures $5, giving a free cash flow of -$9.80M.
| Operating Cash Flow | -9.80M |
| Capital Expenditures | 5 |
| Free Cash Flow | -9.80M |
| FCF Per Share | -0.77 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ACXP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -135.29% |
| FCF Yield | -68.58% |
Analyst Forecast
The average price target for ACXP is $12, which is 1311.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $12 |
| Price Target Difference | 1311.8% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -686.47 |
| Piotroski F-Score | 0 |